Navigation Links
Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
Date:8/27/2008

l to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of regulation of products, the impact of future alliances or transactions and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the Company will continue to face risks related to animal and human testing, to the manufacture of ABthrax and to FDA concurrence that ABthrax meets the requirements of the ABthrax contract. If the Company is unable to meet the product requirements associated with the ABthrax contract, the U.S. government will not be required to reimburse the Company for the costs incurred or to purchase any ABthrax doses. Existing and prospective investors are cautioned not to place undue reli
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)... , March 27, 2015  Delcath Systems, ... and medical device company focused on oncology with ... metastatic liver cancers, announces the reporting of data ... Melphalan Hydrochloride for Injection with the Delcath Hepatic ... poster presentation at the Society of Surgical Oncology ...
(Date:3/26/2015)... WOODBRIDGE, ON , March 26, 2015 /PRNewswire/ - Pivotal ... specialty pharmaceutical company with a focus on Omega-3 therapies ... March 25, 2015 it issued 763,752 common shares of ... payment of interest for the period of December 5 ... on its outstanding Convertible Notes that is due on ...
Breaking Medicine Technology:Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5Pivotal Therapeutics announces payment of interest on outstanding convertible notes 2
... 16, 2011 DecisionView Inc., a leading provider ... for life sciences companies, today announced that a ... Roche have agreed to participate in the creation ... based on real-world clinical performance data. Each of ...
... N.J., June 16, 2011 Ferring Pharmaceuticals Inc. proudly ... Houston in an effort to help increase awareness about ... of healthy aging. The NSG is ... and is organized by the National Senior Games Association, ...
Cached Medicine Technology:DecisionView to Create Clinical Trial Enrollment Benchmarks 2DecisionView to Create Clinical Trial Enrollment Benchmarks 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 2Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 3Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes 4
(Date:3/28/2015)... "Necrorun" was featured on NewsWatch as part ... the latest and coolest applications on the market for ... NewsWatch and technology expert, conducted the app review and ... runner game with knights, nature, and peasants. , ... according to Eurogamer. The popularity of these games grew ...
(Date:3/28/2015)... New York, New York (PRWEB) March 28, 2015 ... ( http://www.vaginalmeshlawsuit2015.com/ ) involving devices manufactured by C.R. ... multidistrict litigation underway in U.S. District Court, Southern ... Jeffrey S. Grand, is serving on the Plaintiffs’ ... March 24th, the Court has granted certain defendants ...
(Date:3/28/2015)... Orlando, FL (PRWEB) March 28, 2015 ... pre-existing conditions coverage is made available to all visitors ... States, effective immediately. All members are encouraged to purchase ... finalized to avoid lack of proper coverage for pre-existing ... suffer from one or two medical conditions with serious ...
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... correlate with a history of shoulder and elbow injuries, according ... for Sports Medicine’s ( AOSSM ) Specialty Day. , “Our ... associated with a 20% increase in likelihood of a history ... is associated with a 12% increase likelihood of a history ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients with ... presented today at the American Orthopaedic Society for Sports ... compared results for 170 patients who received rotator cuff ... capsule release procedure to relieve stiffness at the time ... from St. George Hospital in Sydney, Australia. “Both groups ...
Breaking Medicine News(10 mins):Health News:A Grim Endless Runner Game Was Featured on NewsWatch Television on January 30, 2015 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 2Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 3Health News:Federal C.R. Bard Vaginal Mesh Lawsuits Move Forward, As Court Grants Defense Motion to Amend Responses to Master Complaint 4Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2
... a combined treatment of hormonal therapy and the drug, Herceptin ... breast cancer by over half, according to a recent report. ... the treatment to be made available for even more women ... addition of Herceptin to hormonal therapy kept a control over ...
... The 'baby-boom' of the 1960s and 1970s is largely ... services for people with an intellectual disability // ... reveals that the demand for intellectual disability services is ... of the best levels of service provided and huge ...
... was made at a major conference on brain tumours in ... , ,According to the Irish Cancer Society, in spite of ... rate of success and any damge to the delicate tissue ... there were 316 new cases of primary brain tumour diagnosed ...
... novel method of protection against bird flu has been studied and ... Rochester. // This involves a way of getting around the problem ... months to develop a vaccine. Also, two doses of vaccine would ... study is a" prime and boost" method of vaccination. An initial ...
... would be safer to carry out a stomach-stapling surgery by ... // ,Around 1 million bariatric surgeries ... recommended for weight loss and it involves stapling of the ... ,“Doing the surgery without incisions will make it ...
... mysterious viral outbreak has forced a Canadian University to shut ... This is thought to be a Norwalk-type virus that has ... New Brunswick and in the surrounding university town of Sackville. ... officials to investigate the outbreak. ,"They spent three hours on ...
Cached Medicine News:Health News:Awake Surgery to treat Brain tumours 2Health News:NOTE surgery – to combat obesit 2Health News:Mystery outbreak causes Canadian University to shut down 2
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... disease ELISA products make us a leader ... for faster integration into the busy laboratory, ... reliability and run-to-run consistency. Our Infectious Disease ... a wide range of serological assays including ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: